Noven Pharmaceuticals Inc

Type: Company
Name: Noven Pharmaceuticals Inc
Nationality: United States
First reported Sep 08 2014 - Updated Sep 09 2014 - 1 reports

Untreated hot flashes may be costly for society : study

By By | Reuters  –By Kathryn DoyleNEW YORK (Reuters Health) - The extra healthcare expenses and lost productivity of menopausal women with untreated hot flashes may cost the U.S. billions of dollars each year, a new study suggests.Three-quarters of postmenopausal ... [Published Yahoo! Canada - Sep 08 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Hot flashes can come at a steep cost, study shows

CLEVELAND, Ohio -- Are  hot flashes costing women money? Yes, says a new study led by researchers at Yale University School of Medicine – and paid for by the company that makes a  drug designed to ease the symptoms of the condition synonymous with me ... [Published Cleveland.com - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

Research and Markets (http://www.researchandmarkets.com/research/llvlnb/adhd_therapeutics) has announced the addition of the "" report to their offering. The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 ... [Published Individual.com - Aug 25 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Family Circle Redesign Puts Focus on Nontraditional Families

Meredith’s Family Circle is getting a facelift with its September issue. But the redesign, introduced earlier this month, isn’t just cosmetic—the magazine is also updating its content in an effort to better address its readers’ lives in 2014.“Design trends ... [Published Adweek Online - Aug 20 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 3 reports

Noven Appoints Krista Roberts as Vice President of Operations

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced the appointment of Krista Roberts as the company’s new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, ... [Published Business Wire Health News - Jun 23 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

Noven Announces Settlement of Lidoderm® Patent Litigation

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related ... [Published Business Wire Health News - Apr 16 2014]
First reported Mar 25 2014 - Updated Mar 27 2014 - 3 reports

Noven Pharma's Brisdelle receives US patent to treat VMS associated with menopause

The US Patent and Trademark Office (USPTO) has issued US patent No. 8,658,663, entitled “method of treating thermoregulatory dysfunction with paroxetine” to Noven Pharmaceuticals, Inc. This method of use patent covers the company’s Brisdelle (paroxetine) ... [Published PharmaBiz - Mar 27 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Actavis settles generic Daytrana patent litigation with Noven Pharma

Actavis plc,a global, integrated specialty pharmaceutical company, has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (Methylphenidate Transdermal ... [Published PharmaBiz - Mar 21 2014]

Quotes

...Philip Sarrel, emeritus professor in the Departments of Obstetrics, Gynecology & Reproductive Sciences, and Psychiatry at Yale, wrote. "As a consequence of the steep decline in the use of hormone therapy for VMS since 2002, an increase in the number of working women with untreated menopause symptoms may result in several million more outpatient visits and a rise in healthcare costs reaching several billion dollars."

More Content

All (18) | News (10) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Hisamitsu Pharmaceutical Co., Inc. (4530) - Pro... [Published Research and Markets - Sep 15 2014]
Untreated hot flashes may be costly for society... [Published Yahoo! Canada - Sep 08 2014]
Hot flashes can come at a steep cost, study shows [Published Cleveland.com - Aug 28 2014]
ADHD Therapeutics to 2020 - Broadened Diagnosti... [Published Individual.com - Aug 25 2014]
Family Circle Redesign Puts Focus on Nontraditi... [Published Adweek Online - Aug 20 2014]
Noven Appoints Krista Roberts as Vice President... [Published Business Wire Health News - Jun 23 2014]
Noven Appoints Krista Roberts as Vice President... [Published Business Wire Photo/Multimedia News - Jun 23 2014]
Noven Appoints Krista Roberts as Vice President... [Published Business Wire News with Multimedia - Jun 23 2014]
Noven Announces Settlement of Lidoderm® Patent ... [Published Business Wire Health News - Apr 16 2014]
Noven Pharma's Brisdelle receives US patent to ... [Published PharmaBiz - Mar 27 2014]
Noven Pharmaceuticals announces issuance of new... [Published PBR - News - Mar 26 2014]
Noven Pharmaceuticals Announces Issuance of New... [Published PR Newswire: Policy & Public Interest - Mar 25 2014]
Actavis settles generic Daytrana patent litigat... [Published PharmaBiz - Mar 21 2014]
Actavis to settle patent litigation of Daytrana... [Published Pharmaceutical Business Review - Mar 20 2014]
Actavis Announces Daytrana® Patent Challenge Se... [Published PR Newswire: Policy & Public Interest - Mar 19 2014]
Compliance Congress: Walking the Line [Published Pharmaceutical Executive - Feb 06 2014]
Court Report - Part II [Published Patent Docs - Feb 04 2014]
Noven Pharma inks pact with Shionogi to co-prom... [Published PharmaBiz - Jan 15 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Noven Appoints Krista Roberts as Vice President... [Published Business Wire Health News - Jun 23 2014]
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced the appointment of Krista Roberts as the company’s new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, ...
Noven Appoints Krista Roberts as Vice President... [Published Business Wire Photo/Multimedia News - Jun 23 2014]
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced the appointment of Krista Roberts as the company’s new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, ...
Noven Appoints Krista Roberts as Vice President... [Published Business Wire News with Multimedia - Jun 23 2014]
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced the appointment of Krista Roberts as the company’s new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, ...
Noven Announces Settlement of Lidoderm® Patent ... [Published Business Wire Health News - Apr 16 2014]
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related ...
Noven Pharmaceuticals announces issuance of new... [Published PBR - News - Mar 26 2014]
Noven Pharmaceuticals has announced that the US Patent and Trademark Office has issued US Patent No. 8,658,663, entitled ‘Method Of Treating Thermoregulatory Dysfunction With Paroxetine’. ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.